D
Galectin Therapeutics Inc.
GALT
$1.36
$0.0352.64%
D
Sell
8/10/2023Upgraded
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 8/10/2023 due to an increase in the volatility index.
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 8/10/2023 due to an increase in the volatility index.
E
Sell
7/26/2023Downgrade
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 7/26/2023 due to a decline in the volatility index.
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 7/26/2023 due to a decline in the volatility index.
D
Sell
7/6/2023Upgraded
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index.
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index.
E
Sell
6/20/2023Downgrade
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 6/20/2023 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 49.1% from -$7.24M to -$10.79M, earnings per share declined from -$0.18 to -$0.1938, and debt to equity increased from -1.17 to -1.14.
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 6/20/2023 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 49.1% from -$7.24M to -$10.79M, earnings per share declined from -$0.18 to -$0.1938, and debt to equity increased from -1.17 to -1.14.
D
Sell
11/22/2022Downgrade
Galectin Therapeutics Inc. (GALT) was downgraded to D- from D on 11/22/2022 due to a decline in the volatility index and growth index. Operating cash flow declined 12.37% from -$7.43M to -$8.35M.
Galectin Therapeutics Inc. (GALT) was downgraded to D- from D on 11/22/2022 due to a decline in the volatility index and growth index. Operating cash flow declined 12.37% from -$7.43M to -$8.35M.
D
Sell
8/24/2022Upgraded
Galectin Therapeutics Inc. (GALT) was upgraded to D from D- on 8/24/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 7.63% from -$8.04M to -$7.43M, EBIT increased 2.75% from -$9.94M to -$9.66M, and earnings per share increased from -$0.1671 to -$0.1629.
Galectin Therapeutics Inc. (GALT) was upgraded to D from D- on 8/24/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 7.63% from -$8.04M to -$7.43M, EBIT increased 2.75% from -$9.94M to -$9.66M, and earnings per share increased from -$0.1671 to -$0.1629.
D
Sell
8/3/2022Upgraded
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 8/3/2022 due to an increase in the volatility index and total return index.
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 8/3/2022 due to an increase in the volatility index and total return index.
E
Sell
7/19/2022Downgrade
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 7/19/2022 due to a decline in the volatility index.
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 7/19/2022 due to a decline in the volatility index.
D
Sell
6/21/2022Upgraded
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 6/21/2022 due to an increase in the volatility index and total return index.
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 6/21/2022 due to an increase in the volatility index and total return index.
E
Sell
6/3/2022Downgrade
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 6/3/2022 due to a decline in the volatility index.
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 6/3/2022 due to a decline in the volatility index.
D
Sell
5/19/2022Upgraded
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 5/19/2022 due to a noticeable increase in the valuation index and volatility index.
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 5/19/2022 due to a noticeable increase in the valuation index and volatility index.
E
Sell
5/3/2022Downgrade
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 5/3/2022 due to a decline in the volatility index and total return index.
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 5/3/2022 due to a decline in the volatility index and total return index.
D
Sell
4/18/2022Upgraded
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 4/18/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.1443 to -$0.1228, and EBIT increased 9.93% from -$8.24M to -$7.43M.
Galectin Therapeutics Inc. (GALT) was upgraded to D- from E+ on 4/18/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.1443 to -$0.1228, and EBIT increased 9.93% from -$8.24M to -$7.43M.
E
Sell
3/15/2022Downgrade
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 3/15/2022 due to a large decline in the total return index and volatility index.
Galectin Therapeutics Inc. (GALT) was downgraded to E+ from D- on 3/15/2022 due to a large decline in the total return index and volatility index.
D
Sell
1/7/2022Downgrade
Galectin Therapeutics Inc. (GALT) was downgraded to D- from D on 1/7/2022 due to a noticeable decline in the total return index and volatility index.
Galectin Therapeutics Inc. (GALT) was downgraded to D- from D on 1/7/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell
11/16/2021Upgraded
Galectin Therapeutics Inc. (GALT) was upgraded to D from D- on 11/16/2021 due to an increase in the growth index and volatility index. Operating cash flow increased 16.38% from -$5.98M to -$5M, and earnings per share increased from -$0.146 to -$0.1443.
Galectin Therapeutics Inc. (GALT) was upgraded to D from D- on 11/16/2021 due to an increase in the growth index and volatility index. Operating cash flow increased 16.38% from -$5.98M to -$5M, and earnings per share increased from -$0.146 to -$0.1443.
D
Sell
11/8/2021Downgrade
Galectin Therapeutics Inc. (GALT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index. Earnings per share declined from -$0.111 to -$0.146, and EBIT declined 29.7% from -$6.32M to -$8.19M.
Galectin Therapeutics Inc. (GALT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index. Earnings per share declined from -$0.111 to -$0.146, and EBIT declined 29.7% from -$6.32M to -$8.19M.
D
Sell
5/4/2021Upgraded
Galectin Therapeutics Inc. (GALT) was upgraded to D from D- on 5/4/2021 due to an increase in the total return index and volatility index.
Galectin Therapeutics Inc. (GALT) was upgraded to D from D- on 5/4/2021 due to an increase in the total return index and volatility index.
D
Sell
2/16/2021Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D on 2/16/2021 due to a decline in the valuation index, total return index and volatility index.
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D on 2/16/2021 due to a decline in the valuation index, total return index and volatility index.
D
Sell
1/29/2021Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D from D- on 1/29/2021 due to an increase in the volatility index and valuation index.
Galectin Therapeutics, Inc. (GALT) was upgraded to D from D- on 1/29/2021 due to an increase in the volatility index and valuation index.
D
Sell
1/12/2021Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D on 1/12/2021 due to a noticeable decline in the growth index, valuation index and solvency index. Operating cash flow declined 215.36% from -$2.6M to -$8.21M.
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D on 1/12/2021 due to a noticeable decline in the growth index, valuation index and solvency index. Operating cash flow declined 215.36% from -$2.6M to -$8.21M.
D
Sell
5/12/2020Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D from D- on 5/12/2020 due to a large increase in the growth index. Earnings per share increased from -$0.1225 to -$0.0624, and EBIT increased 30.92% from -$5.19M to -$3.58M.
Galectin Therapeutics, Inc. (GALT) was upgraded to D from D- on 5/12/2020 due to a large increase in the growth index. Earnings per share increased from -$0.1225 to -$0.0624, and EBIT increased 30.92% from -$5.19M to -$3.58M.
D
Sell
5/1/2020Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, total return index and volatility index.
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, total return index and volatility index.
D
Sell
3/17/2020Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to D from D+ on 3/17/2020 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0498 to -$0.1271, operating cash flow declined 154.85% from -$1.48M to -$3.76M, and EBIT declined 81.21% from -$2.86M to -$5.19M.
Galectin Therapeutics, Inc. (GALT) was downgraded to D from D+ on 3/17/2020 due to a major decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0498 to -$0.1271, operating cash flow declined 154.85% from -$1.48M to -$3.76M, and EBIT declined 81.21% from -$2.86M to -$5.19M.
D
Sell
8/13/2019Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D+ from D- on 8/13/2019 due to a major increase in the efficiency index, valuation index and growth index. Total capital increased 643.55% from $6.96M to $51.73M, earnings per share increased from -$0.2022 to -$0.0609, and operating cash flow increased 29.05% from -$3.28M to -$2.33M.
Galectin Therapeutics, Inc. (GALT) was upgraded to D+ from D- on 8/13/2019 due to a major increase in the efficiency index, valuation index and growth index. Total capital increased 643.55% from $6.96M to $51.73M, earnings per share increased from -$0.2022 to -$0.0609, and operating cash flow increased 29.05% from -$3.28M to -$2.33M.
D
Sell
5/15/2019Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D+ on 5/15/2019 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0826 to -$0.2022, and operating cash flow declined 63.63% from -$2.01M to -$3.28M.
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D+ on 5/15/2019 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0826 to -$0.2022, and operating cash flow declined 63.63% from -$2.01M to -$3.28M.
D
Sell
3/7/2019Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D+ from D- on 3/7/2019 due to an increase in the growth index, total return index and solvency index.
Galectin Therapeutics, Inc. (GALT) was upgraded to D+ from D- on 3/7/2019 due to an increase in the growth index, total return index and solvency index.
D
Sell
5/11/2018Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D+ on 5/11/2018 due to a significant decline in the total return index, efficiency index and growth index. Net income declined 78.76% from -$2.38M to -$4.26M, EBIT declined 76.06% from -$2.37M to -$4.18M, and earnings per share declined from -$0.0728 to -$0.1218.
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D+ on 5/11/2018 due to a significant decline in the total return index, efficiency index and growth index. Net income declined 78.76% from -$2.38M to -$4.26M, EBIT declined 76.06% from -$2.37M to -$4.18M, and earnings per share declined from -$0.0728 to -$0.1218.
D
Sell
4/2/2018Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D+ from D on 4/2/2018 due to a major increase in the total return index and efficiency index. Net income increased 45.96% from -$4.41M to -$2.38M.
Galectin Therapeutics, Inc. (GALT) was upgraded to D+ from D on 4/2/2018 due to a major increase in the total return index and efficiency index. Net income increased 45.96% from -$4.41M to -$2.38M.
D
Sell
12/21/2017Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D from D- on 12/21/2017 due to an increase in the total return index and volatility index.
Galectin Therapeutics, Inc. (GALT) was upgraded to D from D- on 12/21/2017 due to an increase in the total return index and volatility index.
D
Sell
12/6/2017Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D on 12/6/2017 due to a decline in the efficiency index, volatility index and valuation index. Total capital declined 54.1% from $5.82M to $2.67M.
Galectin Therapeutics, Inc. (GALT) was downgraded to D- from D on 12/6/2017 due to a decline in the efficiency index, volatility index and valuation index. Total capital declined 54.1% from $5.82M to $2.67M.
D
Sell
8/15/2017Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D from D- on 8/15/2017 due to an increase in the valuation index, growth index and volatility index. Earnings per share increased from -$0.1535 to -$0.14, and EBIT increased 8.73% from -$4.95M to -$4.51M.
Galectin Therapeutics, Inc. (GALT) was upgraded to D from D- on 8/15/2017 due to an increase in the valuation index, growth index and volatility index. Earnings per share increased from -$0.1535 to -$0.14, and EBIT increased 8.73% from -$4.95M to -$4.51M.
D
Sell
4/7/2017Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D- from E+ on 4/7/2017 due to a major increase in the total return index and volatility index.
Galectin Therapeutics, Inc. (GALT) was upgraded to D- from E+ on 4/7/2017 due to a major increase in the total return index and volatility index.
E
Sell
11/9/2016Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to E+ from D- on 11/9/2016 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 4.95 to 3.93.
Galectin Therapeutics, Inc. (GALT) was downgraded to E+ from D- on 11/9/2016 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 4.95 to 3.93.
D
Sell
10/13/2016Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D- from E+ on 10/13/2016 due to an increase in the valuation index.
Galectin Therapeutics, Inc. (GALT) was upgraded to D- from E+ on 10/13/2016 due to an increase in the valuation index.
E
Sell
9/28/2016Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to E+ from D- on 9/28/2016 due to a decline in the volatility index and valuation index.
Galectin Therapeutics, Inc. (GALT) was downgraded to E+ from D- on 9/28/2016 due to a decline in the volatility index and valuation index.
D
Sell
8/10/2016Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D- from E+ on 8/10/2016 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.2432 to -$0.2008, and EBIT increased 6.82% from -$5.94M to -$5.53M.
Galectin Therapeutics, Inc. (GALT) was upgraded to D- from E+ on 8/10/2016 due to a noticeable increase in the growth index and total return index. Earnings per share increased from -$0.2432 to -$0.2008, and EBIT increased 6.82% from -$5.94M to -$5.53M.
E
Sell
8/8/2016Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to E+ from D- on 8/8/2016 due to a decline in the growth index, valuation index and solvency index. The quick ratio declined from 19 to 6.88, EBIT declined 26.76% from -$4.68M to -$5.94M, and earnings per share declined from -$0.1919 to -$0.2432.
Galectin Therapeutics, Inc. (GALT) was downgraded to E+ from D- on 8/8/2016 due to a decline in the growth index, valuation index and solvency index. The quick ratio declined from 19 to 6.88, EBIT declined 26.76% from -$4.68M to -$5.94M, and earnings per share declined from -$0.1919 to -$0.2432.
D
Sell
3/16/2016Upgraded
Galectin Therapeutics, Inc. (GALT) was upgraded to D- from E+ on 3/16/2016 due to an increase in the growth index and solvency index. The quick ratio increased from 12.35 to 19, earnings per share increased from -$0.2586 to -$0.1958, and EBIT increased 20.61% from -$5.9M to -$4.68M.
Galectin Therapeutics, Inc. (GALT) was upgraded to D- from E+ on 3/16/2016 due to an increase in the growth index and solvency index. The quick ratio increased from 12.35 to 19, earnings per share increased from -$0.2586 to -$0.1958, and EBIT increased 20.61% from -$5.9M to -$4.68M.
E
Sell
3/11/2016Downgrade
Galectin Therapeutics, Inc. (GALT) was downgraded to E+ from D on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 26.79% from -$4.64M to -$5.89M, and total capital declined 20.12% from $24.77M to $19.79M.
Galectin Therapeutics, Inc. (GALT) was downgraded to E+ from D on 3/11/2016 due to a significant decline in the volatility index, total return index and efficiency index. Net income declined 26.79% from -$4.64M to -$5.89M, and total capital declined 20.12% from $24.77M to $19.79M.
NASDAQ
04/08/2025 10:55AM Eastern
Quotes delayed
